You are viewing the site in preview mode
Skip to main content
| | |
Degarelix (Continued group)
|
Conversion from degarelix to GnRH agonist (Changed group)
|
p value
|
|---|
|
Number of patients
| | |
51
| |
57
| |
|
Follow up duration (months)
|
median (range)
|
19.4
|
(1.0–57.9)
|
38.8
|
(2.2–58.6)
|
< 0.001
|
|
Degarelix treatment duration (months)
|
median (range)
|
14
|
(1–52)
|
8
|
(1–39)
|
0.064
|
|
Age (years)
|
median (range)
|
73
|
(49–95)
|
75
|
(50–90)
|
0.572
|
|
T stage
|
T1
|
3
|
5.9%
|
1
|
1.8%
|
0.387
|
|
T2
|
10
|
19.6%
|
18
|
31.6%
|
|
T3
|
24
|
47.1%
|
26
|
45.6%
|
|
T4
|
14
|
27.4%
|
12
|
21.1%
|
|
N
|
N0
|
29
|
56.9%
|
31
|
54.4%
|
0.796
|
|
N1
|
22
|
43.1%
|
26
|
45.6%
|
|
M
|
M0
|
16
|
31.4%
|
23
|
40.4%
|
0.486
|
|
M1
|
35
|
68.6%
|
34
|
59.6%
|
|
Gleason score
|
6
|
1
|
2.0%
|
2
|
3.5%
|
0.389
|
|
7
|
5
|
9.8%
|
6
|
10.5%
|
|
8
|
21
|
41.2%
|
24
|
42.1%
|
|
9
|
15
|
29.4%
|
15
|
26.3%
|
|
10
|
4
|
7.8%
|
5
|
8.8%
|
|
unknown
|
5
|
9.8%
|
5
|
8.8%
| |
|
Initial PSA (ng/ml)
|
Median (range)
|
145
|
(0.48–8072)
|
122
|
(5.62–9675)
|
0.669
|
|
PSA
|
PSA 0–4
|
1
|
2.0%
|
0
|
0.0%
|
0.415
|
|
PSA4–10
|
5
|
9.8%
|
3
|
5.3%
|
|
PSA10–20
|
2
|
3.9%
|
5
|
8.8%
|
|
PSA > 20
|
43
|
84.3%
|
49
|
86.0%
|
|
Treatment
|
CAB
|
48
|
94.1%
|
54
|
94.7%
|
0.889
|
|
GnRH only
|
3
|
5.9%
|
3
|
5.3%
|
|
Transition to CRPC
|
No
|
37
|
72.5%
|
38
|
66.7%
|
0.508
|
|
Yes
|
14
|
27.5%
|
19
|
33.3%
|
|
% PSA decrease by degarelix
|
median (range)
|
−99.4%
|
(6.6–100.0)
|
−99.8%
|
(47.2–100.0)
|
0.068
|
- Abbreviations CAB combined androgen blockade, CRPC castration resistant prostate cancer, GnRH gonadotropin releasing hormone
